TREATMENT WITH AGONISTS OF TOLL-LIKE RECEPTORS

Mammals are treated with agonists of bacterially-activated TLRs. The agonist are administered orally or mucosally. In one embodiment, the mammal treated is subject to a gastro-intestinal injury. The agonist can be administered prior to infliction of the gastro-intestinal injury, subsequent to inflic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	MEDZHITOV, RUSLAN, M
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINSTCLIMATE CHANGE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Mammals are treated with agonists of bacterially-activated TLRs. The agonist are administered orally or mucosally. In one embodiment, the mammal treated is subject to a gastro-intestinal injury. The agonist can be administered prior to infliction of the gastro-intestinal injury, subsequent to infliction of the gastrointestinal injury and concurrently with infliction of the gastro-intestinal injury. In another embodiment, the mammal is subject to tissue damage. The agonist is administered prior to the primary treatment, following the primary treatment or concurrently with the primary treatment. Selon l'invention, des mammifères sont traités avec des agonistes des TLR à activation bactérienne. Les agonistes sont administrés par voie orale ou muqueuse. Dans un mode de réalisation, une lésion gastro-intestinale est provoquée chez le mammifère traité. Les agonistes peuvent être administrés avant, pendant ou après infliction de la lésion gastro-intestinale. Dans un autre mode de réalisation, une dégradation tissulaire est provoquée chez le mammifère. L'agoniste est administré avant, pendant ou après le traitement principal.